Antibodies for il-17c

Abstract

The present invention provides antibodies or antibody fragments binding to human IL-17C. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment of humans having, for example, atopic dermatitis or psoriasis.

1 : An antibody or antibody fragment specific for IL-17C wherein said antibody or antibody fragment cross-competes with an antibody comprising
 (a) the HCDR1 region of SEQ ID No.: 7, the HCDR2 region of SEQ ID No.: 8, the HCDR3 region of SEQ ID No.: 9, the LCDR1 region of SEQ ID No.: 13, the LCDR2 region of SEQ ID No.: 14 and the LCDR3 region of SEQ ID No.: 15, or   (b) the HCDR1 region of SEQ ID No.: 20, the HCDR2 region of SEQ ID No.: 21, the HCDR3 region of SEQ ID No.: 22, the LCDR1 region of SEQ ID No.: 26, the LCDR2 region of SEQ ID No.: 27 and the LCDR3 region of SEQ ID No.: 28.   
     
     
         2 : An antibody or antibody fragment specific for IL-17C wherein said antibody or antibody fragment comprises
 (a) a HCDR1 region comprising the amino acid sequence of SEQ ID No.: 7, a HCDR2 region comprising the amino acid sequence of SEQ ID No.: 8, a HCDR3 region comprising the amino acid sequence of SEQ ID No.: 9, a LCDR1 region comprising the amino acid sequence of SEQ ID No.: 13, a LCDR2 region comprising the amino acid sequence of SEQ ID No.: 14 and a LCDR3 region comprising the amino acid sequence of SEQ ID No.: 15, or   (b) a HCDR1 region comprising the amino acid sequence of SEQ ID No.: 20, a HCDR2 region comprising the amino acid sequence of SEQ ID No.: 21, a HCDR3 region comprising the amino acid sequence of SEQ ID No.: 22, a LCDR1 region comprising the amino acid sequence of SEQ ID No.: 26, a LCDR2 region comprising the amino acid sequence of SEQ ID No.: 27 and a LCDR3 region comprising the amino acid sequence of SEQ ID No.: 28.   
     
     
         3 : An antibody or antibody fragment according to  claim 2  wherein said antibody or antibody fragment comprises
 (a) a HCDR1 region of SEQ ID No.: 7, the HCDR2 region of SEQ ID No.: 8, the HCDR3 region of SEQ ID No.: 9, the LCDR1 region of SEQ ID No.: 13, the LCDR2 region of SEQ ID No.: 14 and the LCDR3 region of SEQ ID No.: 15, or 
 (b) a HCDR1 region of SEQ ID No.: 20, the HCDR2 region of SEQ ID No.: 21, the HCDR3 region of SEQ ID No.: 22, the LCDR1 region of SEQ ID No.: 26, the LCDR2 region of SEQ ID No.: 27 and the LCDR3 region of SEQ ID No.: 28. 
 
     
     
         4 : An antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment is specific for human IL-17C. 
     
     
         5 : An isolated antibody or antibody fragment according to  claim 4 , wherein said antibody or antibody fragment is specific for human IL-17C, cynomolgus IL-17C and mouse IL-17C. 
     
     
         6 : The antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment is a human, humanized or chimeric antibody or antibody fragment. 
     
     
         7 : An antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID No.: 17 and a light chain of SEQ ID No.: 16. 
     
     
         8 : An antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment comprises a heavy chain of SEQ ID No.: 30 and a light chain of SEQ ID No.: 29. 
     
     
         9 : An antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment is an isolated antibody or antibody fragment. 
     
     
         10 : An antibody or antibody fragment according to  claim 1 , wherein said antibody or antibody fragment is a recombinant antibody or antibody fragment. 
     
     
         11 . (canceled) 
     
     
         12 : A nucleic acid composition comprising a nucleic acid sequence or a plurality of nucleic acid sequences encoding the antibody or antibody fragment according to  claim 1 . 
     
     
         13 : A vector composition comprising a vector or a plurality of vectors comprising the nucleic acid sequence or plurality of nucleic acid sequences of  claim 12 . 
     
     
         14 : A cell comprising the vector composition of  claim 13 . 
     
     
         15 : A pharmaceutical composition comprising the antibody or antibody fragment according to  claim 1  and a pharmaceutically acceptable carrier or excipient. 
     
     
         16 : A method for treating a subject with an inflammatory disorder, said method comprising administering the antibody or antibody fragment of  claim 1  to the subject.